Literature DB >> 21300973

Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.

A Vennegoor1, M P Wattjes, E T L van Munster, R L Kriekaart, B W van Oosten, F Barkhof, J Killestein, C H Polman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21300973     DOI： 10.1212/WNL.0b013e31820b7644

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  8 in total

1.  Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem.

Authors:  Joachim Havla; Reinhard Hohlfeld; Tania Kümpfel
Journal:  J Neurol       Date:  2013-11-26       Impact factor: 4.849

2.  Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report.

Authors:  Maria Sepúlveda; Sara Llufriu; Yolanda Blanco; Nuria Solà-Valls; Delon La Puma; Joan Berenguer; Pablo Villoslada; Albert Saiz
Journal:  J Neurol       Date:  2014-11-20       Impact factor: 4.849

3.  Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Clemens Warnke; Gloria von Geldern; Philipp Markwerth; Thomas Dehmel; Robert Hoepner; Ralf Gold; Michael Pawlita; Tania Kümpfel; Mathias Mäurer; Martin Stangel; Florian Wegner; Reinhard Hohlfeld; Vera Straeten; Volker Limmroth; Thomas Weber; Derik Hermsen; Christoph Kleinschnitz; Hans-Peter Hartung; Mike P Wattjes; Anders Svenningson; Eugene Major; Tomas Olsson; Bernd C Kieseier; Ortwin Adams
Journal:  Ann Neurol       Date:  2014-05-08       Impact factor: 10.422

4.  Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Authors:  Roderick P P W M Maas; Annemarie H G Muller-Hansma; Rianne A J Esselink; Jean-Luc Murk; Clemens Warnke; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2016-07-11       Impact factor: 4.849

5.  Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.

Authors:  Stefanie Dahlhaus; Robert Hoepner; Andrew Chan; Ingo Kleiter; Ortwin Adams; Carsten Lukas; Kerstin Hellwig; Ralf Gold
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-04-19       Impact factor: 10.154

6.  Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

Authors:  Tuan Dong-Si; Sandra Richman; Mike P Wattjes; Made Wenten; Sarah Gheuens; Jeffrey Philip; Shoibal Datta; James McIninch; Carmen Bozic; Gary Bloomgren; Nancy Richert
Journal:  Ann Clin Transl Neurol       Date:  2014-10-09       Impact factor: 4.511

Review 7.  Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

Authors:  C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-10-22       Impact factor: 10.154

Review 8.  Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.

Authors:  Irene Cortese; Daniel S Reich; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2020-11-20       Impact factor: 42.937
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.